EuropeFX has recently expanded its own offering to include a basket of seven Pharma Stocks.
FM
2020 has been defined by the outbreak of Covid-19, which according to many health experts has yet to even reach its peak.
To date, a vaccine has not yet been created to combat the virus, though pharmaceutical companies worldwide are aggressively pursuing one.
This has made investing in pharmaceutical stocks one of the most attractive options in 2020, given the huge potential upside of rolling out the first vaccine for Covid-19.
EuropeFX is clearly cognizant of this demand, having recently expanded its own offering to include a basket of Pharma Stocks.
The brokerage is now offering exposure into seven different pharmaceutical companies that are currently the frontrunners for a Covid-19 vaccine.
Why Now Could Be an Interesting Time to Invest in Pharma Stocks
Hundreds of thousands have died worldwide and the demand for a vaccine has never been higher. This has created an unprecedented demand, which could catapult a pharmaceutical’s valuation through the roof overnight.
Traditionally, pharmaceutical companies face long roads to inventing vaccines. Long before these get to the market, a vaccine has to pass multiple stages of trials to ensure its safety.
These are decreased, however, once the World Health Organization (WHO) has announced a pandemic, which is the case for Covid-19.
As a result, several pharmaceutical companies have seen an extraordinary level of speculative interest from investors during the trial stages of a vaccine.
Which Companies Could You Invest in?
EuropeFX now has seven pharmaceutical companies leading the race for a Covid-19 vaccine globally on offer. This includes the following companies:
Gilead Sciences Inc.
(NASDAQ:GILD)
A research-based biopharmaceutical company, Gilead Sciences, currently carries over twenty-five marketed treatments in the United States for HIV and Aids, Liver Diseases, Hematology and Oncology, Cardiovascular Disease and Inflammation and Respiratory Disease. Gilead is currently in Phase-3 trials for Remdesivir, a Covid-19 drug.
Merck KGaA
(NYSE:MRK)
Founded in Darmstadt, Germany, Merck & Co is active in sixty-six countries and with around 57,000 employees, the Company generated sales of €16.2 billion in 2019. The Company is active in all areas of pharmaceutical production and food safety and is heavily involved in the performance material sector for a broad and diverse range of industries.
Amgen Inc.
(NASDAQ:AMGN)
Founded in the United States in 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies. Amgen is currently focused on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. The Company generated sales of $22.2 billion in 2019.
Dynavax Technologies Inc.
(NASDAQ:DVAX)
Dynavax Technologies Corporation develops and commercializes novel vaccines. The Company’s first commercial product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], a hepatitis B vaccine for adults, is approved in the United States. 2019 saw product revenue of $34.6 million.
Biogen Inc.
(NASDAQ:BIIB)
Founded in Geneva, Switzerland, Biogen helped pioneer the biotechnology industry. A leader in the development of treatments for Multiple Sclerosis, Spinal Muscular Atrophy, and Alzheimer’s Disease, Biogen’s revenues in 2019 were over $14.3 billion, for a 4.5% increase in total revenues year over year.
Biotest Aktiengesellschaft
(XETRA:BIO3.DE)
Founded in Germany, Biotest markets different products in three therapeutic areas: clinical immunology, haematology, and intensive care medicine. The Company is active globally, with locations in Europe, South America, and the Russian Federation. 2019 saw revenues of over €419 million, and the Company embarked on an ambitious expansion program with investments of over €300 million planned for their Dreieich location with the creation of over 300 new jobs in the region.
Moderna, Inc
(NASDAQ:MRNA)
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
Risk Warning: CFDs are complex instruments and carry a high risk of losing money quickly due to leverage. 78.94% of retail investor accounts lose money when trading CFDs with this provider. The information contained in this market overview should in no way be construed as investment advice and/or as a proposal and/or request for trading activities and financial transactions. The data contained in this market overview is not necessarily real-time or error-free. The data and prices on the material are not necessarily provided by a market or exchange, but by market makers, so that prices may not be accurate and may differ from the actual price in a particular market, meaning that prices are indicative and not suitable for trading purposes. There is no guarantee and/or prediction of future performance. EuropeFX, its affiliates, agents, directors or employees do not guarantee the accuracy or validity of any information or data provided and shall not be liable for any loss arising from any investment based thereon. Trading Forex/CFD's carries a high level of risk and may result in the loss of your entire investment. Forex/CFD's are leveraged products and therefore trading Forex/CFD's may not be suitable for all investors. It is recommended not to invest more money than you can afford to lose in order to avoid significant financial problems in case of losses. Please make sure that you define the maximum risk for yourself.
2020 has been defined by the outbreak of Covid-19, which according to many health experts has yet to even reach its peak.
To date, a vaccine has not yet been created to combat the virus, though pharmaceutical companies worldwide are aggressively pursuing one.
This has made investing in pharmaceutical stocks one of the most attractive options in 2020, given the huge potential upside of rolling out the first vaccine for Covid-19.
EuropeFX is clearly cognizant of this demand, having recently expanded its own offering to include a basket of Pharma Stocks.
The brokerage is now offering exposure into seven different pharmaceutical companies that are currently the frontrunners for a Covid-19 vaccine.
Why Now Could Be an Interesting Time to Invest in Pharma Stocks
Hundreds of thousands have died worldwide and the demand for a vaccine has never been higher. This has created an unprecedented demand, which could catapult a pharmaceutical’s valuation through the roof overnight.
Traditionally, pharmaceutical companies face long roads to inventing vaccines. Long before these get to the market, a vaccine has to pass multiple stages of trials to ensure its safety.
These are decreased, however, once the World Health Organization (WHO) has announced a pandemic, which is the case for Covid-19.
As a result, several pharmaceutical companies have seen an extraordinary level of speculative interest from investors during the trial stages of a vaccine.
Which Companies Could You Invest in?
EuropeFX now has seven pharmaceutical companies leading the race for a Covid-19 vaccine globally on offer. This includes the following companies:
Gilead Sciences Inc.
(NASDAQ:GILD)
A research-based biopharmaceutical company, Gilead Sciences, currently carries over twenty-five marketed treatments in the United States for HIV and Aids, Liver Diseases, Hematology and Oncology, Cardiovascular Disease and Inflammation and Respiratory Disease. Gilead is currently in Phase-3 trials for Remdesivir, a Covid-19 drug.
Merck KGaA
(NYSE:MRK)
Founded in Darmstadt, Germany, Merck & Co is active in sixty-six countries and with around 57,000 employees, the Company generated sales of €16.2 billion in 2019. The Company is active in all areas of pharmaceutical production and food safety and is heavily involved in the performance material sector for a broad and diverse range of industries.
Amgen Inc.
(NASDAQ:AMGN)
Founded in the United States in 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies. Amgen is currently focused on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. The Company generated sales of $22.2 billion in 2019.
Dynavax Technologies Inc.
(NASDAQ:DVAX)
Dynavax Technologies Corporation develops and commercializes novel vaccines. The Company’s first commercial product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], a hepatitis B vaccine for adults, is approved in the United States. 2019 saw product revenue of $34.6 million.
Biogen Inc.
(NASDAQ:BIIB)
Founded in Geneva, Switzerland, Biogen helped pioneer the biotechnology industry. A leader in the development of treatments for Multiple Sclerosis, Spinal Muscular Atrophy, and Alzheimer’s Disease, Biogen’s revenues in 2019 were over $14.3 billion, for a 4.5% increase in total revenues year over year.
Biotest Aktiengesellschaft
(XETRA:BIO3.DE)
Founded in Germany, Biotest markets different products in three therapeutic areas: clinical immunology, haematology, and intensive care medicine. The Company is active globally, with locations in Europe, South America, and the Russian Federation. 2019 saw revenues of over €419 million, and the Company embarked on an ambitious expansion program with investments of over €300 million planned for their Dreieich location with the creation of over 300 new jobs in the region.
Moderna, Inc
(NASDAQ:MRNA)
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
Risk Warning: CFDs are complex instruments and carry a high risk of losing money quickly due to leverage. 78.94% of retail investor accounts lose money when trading CFDs with this provider. The information contained in this market overview should in no way be construed as investment advice and/or as a proposal and/or request for trading activities and financial transactions. The data contained in this market overview is not necessarily real-time or error-free. The data and prices on the material are not necessarily provided by a market or exchange, but by market makers, so that prices may not be accurate and may differ from the actual price in a particular market, meaning that prices are indicative and not suitable for trading purposes. There is no guarantee and/or prediction of future performance. EuropeFX, its affiliates, agents, directors or employees do not guarantee the accuracy or validity of any information or data provided and shall not be liable for any loss arising from any investment based thereon. Trading Forex/CFD's carries a high level of risk and may result in the loss of your entire investment. Forex/CFD's are leveraged products and therefore trading Forex/CFD's may not be suitable for all investors. It is recommended not to invest more money than you can afford to lose in order to avoid significant financial problems in case of losses. Please make sure that you define the maximum risk for yourself.
In this video, we take an in-depth look at @Exness , a global multi-asset broker operating since 2008, known for fast withdrawals, flexible account types, and strong regulatory coverage across multiple regions.
We break down Exness’s regulatory framework, supported trading platforms including MetaTrader 4, MetaTrader 5, Exness Terminal, and the Exness Trade App, as well as available account types such as Standard, Pro, Zero, and Raw Spread.
You’ll also learn about Exness’s leverage options, fees and commissions, swap-free trading, available instruments across forex, commodities, indices, stocks, and cryptocurrencies, and what traders can expect in terms of execution, funding speed, and customer support.
Watch the full review to see whether Exness aligns with your trading goals and strategy.
👉 Explore Exness’s full broker listing on the Finance Magnates Directory:
https://directory.financemagnates.com/multi-asset-brokers/exness/
📣 Stay up to date with the latest in finance and trading. Follow Finance Magnates for industry news, insights, and global event coverage.
Connect with us:
🔗 LinkedIn: /financemagnates
👍 Facebook: /financemagnates
📸 Instagram: https://www.instagram.com/financemagnates
🐦 X: https://x.com/financemagnates
🎥 TikTok: https://www.tiktok.com/tag/financemagnates
▶️ YouTube: /@financemagnates_official
#Exness #ExnessReview #Forex #FinanceMagnates #ForexBroker #BrokerReview #CFDTrading #OnlineTrading #MarketInsights
In this video, we take an in-depth look at @Exness , a global multi-asset broker operating since 2008, known for fast withdrawals, flexible account types, and strong regulatory coverage across multiple regions.
We break down Exness’s regulatory framework, supported trading platforms including MetaTrader 4, MetaTrader 5, Exness Terminal, and the Exness Trade App, as well as available account types such as Standard, Pro, Zero, and Raw Spread.
You’ll also learn about Exness’s leverage options, fees and commissions, swap-free trading, available instruments across forex, commodities, indices, stocks, and cryptocurrencies, and what traders can expect in terms of execution, funding speed, and customer support.
Watch the full review to see whether Exness aligns with your trading goals and strategy.
👉 Explore Exness’s full broker listing on the Finance Magnates Directory:
https://directory.financemagnates.com/multi-asset-brokers/exness/
📣 Stay up to date with the latest in finance and trading. Follow Finance Magnates for industry news, insights, and global event coverage.
Connect with us:
🔗 LinkedIn: /financemagnates
👍 Facebook: /financemagnates
📸 Instagram: https://www.instagram.com/financemagnates
🐦 X: https://x.com/financemagnates
🎥 TikTok: https://www.tiktok.com/tag/financemagnates
▶️ YouTube: /@financemagnates_official
#Exness #ExnessReview #Forex #FinanceMagnates #ForexBroker #BrokerReview #CFDTrading #OnlineTrading #MarketInsights
In this video, we take an in-depth look at @Exness , a global multi-asset broker operating since 2008, known for fast withdrawals, flexible account types, and strong regulatory coverage across multiple regions.
We break down Exness’s regulatory framework, supported trading platforms including MetaTrader 4, MetaTrader 5, Exness Terminal, and the Exness Trade App, as well as available account types such as Standard, Pro, Zero, and Raw Spread.
You’ll also learn about Exness’s leverage options, fees and commissions, swap-free trading, available instruments across forex, commodities, indices, stocks, and cryptocurrencies, and what traders can expect in terms of execution, funding speed, and customer support.
Watch the full review to see whether Exness aligns with your trading goals and strategy.
👉 Explore Exness’s full broker listing on the Finance Magnates Directory:
https://directory.financemagnates.com/multi-asset-brokers/exness/
📣 Stay up to date with the latest in finance and trading. Follow Finance Magnates for industry news, insights, and global event coverage.
Connect with us:
🔗 LinkedIn: /financemagnates
👍 Facebook: /financemagnates
📸 Instagram: https://www.instagram.com/financemagnates
🐦 X: https://x.com/financemagnates
🎥 TikTok: https://www.tiktok.com/tag/financemagnates
▶️ YouTube: /@financemagnates_official
#Exness #ExnessReview #Forex #FinanceMagnates #ForexBroker #BrokerReview #CFDTrading #OnlineTrading #MarketInsights
In this video, we take an in-depth look at @Exness , a global multi-asset broker operating since 2008, known for fast withdrawals, flexible account types, and strong regulatory coverage across multiple regions.
We break down Exness’s regulatory framework, supported trading platforms including MetaTrader 4, MetaTrader 5, Exness Terminal, and the Exness Trade App, as well as available account types such as Standard, Pro, Zero, and Raw Spread.
You’ll also learn about Exness’s leverage options, fees and commissions, swap-free trading, available instruments across forex, commodities, indices, stocks, and cryptocurrencies, and what traders can expect in terms of execution, funding speed, and customer support.
Watch the full review to see whether Exness aligns with your trading goals and strategy.
👉 Explore Exness’s full broker listing on the Finance Magnates Directory:
https://directory.financemagnates.com/multi-asset-brokers/exness/
📣 Stay up to date with the latest in finance and trading. Follow Finance Magnates for industry news, insights, and global event coverage.
Connect with us:
🔗 LinkedIn: /financemagnates
👍 Facebook: /financemagnates
📸 Instagram: https://www.instagram.com/financemagnates
🐦 X: https://x.com/financemagnates
🎥 TikTok: https://www.tiktok.com/tag/financemagnates
▶️ YouTube: /@financemagnates_official
#Exness #ExnessReview #Forex #FinanceMagnates #ForexBroker #BrokerReview #CFDTrading #OnlineTrading #MarketInsights
The FMLS:25 highlights video is now live - a look back at the conversations, the energy on the floor, and the moments that shaped this year’s summit.
While that’s still fresh, the next launches across the FM Events portfolio are already taking shape.
FM Singapore takes place on the 12-14 of May, connecting the APAC market with its own distinct audience and priorities. FMAS:26 heads to Cape Town on 26–27 May shortly after, bringing the focus to Africa’s trading and fintech ecosystem.
Different regions. Different audiences. Same commitment to building the right rooms for meaningful conversations.
More details coming very soon. The launches are imminent. - here you go
The FMLS:25 highlights video is now live - a look back at the conversations, the energy on the floor, and the moments that shaped this year’s summit.
While that’s still fresh, the next launches across the FM Events portfolio are already taking shape.
FM Singapore takes place on the 12-14 of May, connecting the APAC market with its own distinct audience and priorities. FMAS:26 heads to Cape Town on 26–27 May shortly after, bringing the focus to Africa’s trading and fintech ecosystem.
Different regions. Different audiences. Same commitment to building the right rooms for meaningful conversations.
More details coming very soon. The launches are imminent. - here you go
The FMLS:25 highlights video is now live - a look back at the conversations, the energy on the floor, and the moments that shaped this year’s summit.
While that’s still fresh, the next launches across the FM Events portfolio are already taking shape.
FM Singapore takes place on the 12-14 of May, connecting the APAC market with its own distinct audience and priorities. FMAS:26 heads to Cape Town on 26–27 May shortly after, bringing the focus to Africa’s trading and fintech ecosystem.
Different regions. Different audiences. Same commitment to building the right rooms for meaningful conversations.
More details coming very soon. The launches are imminent. - here you go
The FMLS:25 highlights video is now live - a look back at the conversations, the energy on the floor, and the moments that shaped this year’s summit.
While that’s still fresh, the next launches across the FM Events portfolio are already taking shape.
FM Singapore takes place on the 12-14 of May, connecting the APAC market with its own distinct audience and priorities. FMAS:26 heads to Cape Town on 26–27 May shortly after, bringing the focus to Africa’s trading and fintech ecosystem.
Different regions. Different audiences. Same commitment to building the right rooms for meaningful conversations.
More details coming very soon. The launches are imminent. - here you go
The FMLS:25 highlights video is now live - a look back at the conversations, the energy on the floor, and the moments that shaped this year’s summit.
While that’s still fresh, the next launches across the FM Events portfolio are already taking shape.
FM Singapore takes place on the 12-14 of May, connecting the APAC market with its own distinct audience and priorities. FMAS:26 heads to Cape Town on 26–27 May shortly after, bringing the focus to Africa’s trading and fintech ecosystem.
Different regions. Different audiences. Same commitment to building the right rooms for meaningful conversations.
More details coming very soon. The launches are imminent. - here you go
The FMLS:25 highlights video is now live - a look back at the conversations, the energy on the floor, and the moments that shaped this year’s summit.
While that’s still fresh, the next launches across the FM Events portfolio are already taking shape.
FM Singapore takes place on the 12-14 of May, connecting the APAC market with its own distinct audience and priorities. FMAS:26 heads to Cape Town on 26–27 May shortly after, bringing the focus to Africa’s trading and fintech ecosystem.
Different regions. Different audiences. Same commitment to building the right rooms for meaningful conversations.
More details coming very soon. The launches are imminent. - here you go
What sources does the Finance Magnates newsroom rely on before publishing a story? #FinanceNews
What sources does the Finance Magnates newsroom rely on before publishing a story? #FinanceNews
What sources does the Finance Magnates newsroom rely on before publishing a story? #FinanceNews
What sources does the Finance Magnates newsroom rely on before publishing a story? #FinanceNews
What sources does the Finance Magnates newsroom rely on before publishing a story? #FinanceNews
What sources does the Finance Magnates newsroom rely on before publishing a story? #FinanceNews
Yam Yehoshua, Editor-in-Chief at Finance Magnates, explains the editorial process: direct industry sources, reports, regulators, social media signals, and thorough cross-checking before anything goes live.
📰 Industry sources
📊 Reports & regulators
🔎 Verification before publication
Yam Yehoshua, Editor-in-Chief at Finance Magnates, explains the editorial process: direct industry sources, reports, regulators, social media signals, and thorough cross-checking before anything goes live.
📰 Industry sources
📊 Reports & regulators
🔎 Verification before publication
Yam Yehoshua, Editor-in-Chief at Finance Magnates, explains the editorial process: direct industry sources, reports, regulators, social media signals, and thorough cross-checking before anything goes live.
📰 Industry sources
📊 Reports & regulators
🔎 Verification before publication
Yam Yehoshua, Editor-in-Chief at Finance Magnates, explains the editorial process: direct industry sources, reports, regulators, social media signals, and thorough cross-checking before anything goes live.
📰 Industry sources
📊 Reports & regulators
🔎 Verification before publication
Yam Yehoshua, Editor-in-Chief at Finance Magnates, explains the editorial process: direct industry sources, reports, regulators, social media signals, and thorough cross-checking before anything goes live.
📰 Industry sources
📊 Reports & regulators
🔎 Verification before publication
Yam Yehoshua, Editor-in-Chief at Finance Magnates, explains the editorial process: direct industry sources, reports, regulators, social media signals, and thorough cross-checking before anything goes live.
📰 Industry sources
📊 Reports & regulators
🔎 Verification before publication
OnePrime’s Jerry Khargi on Infrastructure, Liquidity & Trust | Executive Interview
OnePrime’s Jerry Khargi on Infrastructure, Liquidity & Trust | Executive Interview
OnePrime’s Jerry Khargi on Infrastructure, Liquidity & Trust | Executive Interview
OnePrime’s Jerry Khargi on Infrastructure, Liquidity & Trust | Executive Interview
OnePrime’s Jerry Khargi on Infrastructure, Liquidity & Trust | Executive Interview
OnePrime’s Jerry Khargi on Infrastructure, Liquidity & Trust | Executive Interview
Recorded live at FMLS:25 London, this exclusive executive interview features Jerry Khargi, Executive Director at OnePrime, in conversation with Andrea Badiola Mateos from Finance Magnates.
In this in-depth discussion, Jerry shares:
- OnePrime’s journey from a retail-focused business to a global institutional liquidity provider
- What truly sets award-winning trading infrastructure apart
- Key trends shaping institutional trading, including technology and AI
- The importance of transparency, ethics, and reputation in long-term success
- OnePrime’s vision for growth over the next 12–24 months
Fresh from winning Finance Magnates’ Best Trading Infrastructure Broker, Jerry explains how experience, mentorship, and real-world problem solving form the “special sauce” behind OnePrime’s institutional offering.
🏆 Award Highlight: Best Trading Infrastructure Broker
👉 Subscribe to Finance Magnates for more executive interviews, market insights, and exclusive coverage from the world’s leading financial events.
#FMLS25 #FinanceMagnates #OnePrime #InstitutionalTrading #Liquidity #TradingInfrastructure #ExecutiveInterview
Recorded live at FMLS:25 London, this exclusive executive interview features Jerry Khargi, Executive Director at OnePrime, in conversation with Andrea Badiola Mateos from Finance Magnates.
In this in-depth discussion, Jerry shares:
- OnePrime’s journey from a retail-focused business to a global institutional liquidity provider
- What truly sets award-winning trading infrastructure apart
- Key trends shaping institutional trading, including technology and AI
- The importance of transparency, ethics, and reputation in long-term success
- OnePrime’s vision for growth over the next 12–24 months
Fresh from winning Finance Magnates’ Best Trading Infrastructure Broker, Jerry explains how experience, mentorship, and real-world problem solving form the “special sauce” behind OnePrime’s institutional offering.
🏆 Award Highlight: Best Trading Infrastructure Broker
👉 Subscribe to Finance Magnates for more executive interviews, market insights, and exclusive coverage from the world’s leading financial events.
#FMLS25 #FinanceMagnates #OnePrime #InstitutionalTrading #Liquidity #TradingInfrastructure #ExecutiveInterview
Recorded live at FMLS:25 London, this exclusive executive interview features Jerry Khargi, Executive Director at OnePrime, in conversation with Andrea Badiola Mateos from Finance Magnates.
In this in-depth discussion, Jerry shares:
- OnePrime’s journey from a retail-focused business to a global institutional liquidity provider
- What truly sets award-winning trading infrastructure apart
- Key trends shaping institutional trading, including technology and AI
- The importance of transparency, ethics, and reputation in long-term success
- OnePrime’s vision for growth over the next 12–24 months
Fresh from winning Finance Magnates’ Best Trading Infrastructure Broker, Jerry explains how experience, mentorship, and real-world problem solving form the “special sauce” behind OnePrime’s institutional offering.
🏆 Award Highlight: Best Trading Infrastructure Broker
👉 Subscribe to Finance Magnates for more executive interviews, market insights, and exclusive coverage from the world’s leading financial events.
#FMLS25 #FinanceMagnates #OnePrime #InstitutionalTrading #Liquidity #TradingInfrastructure #ExecutiveInterview
Recorded live at FMLS:25 London, this exclusive executive interview features Jerry Khargi, Executive Director at OnePrime, in conversation with Andrea Badiola Mateos from Finance Magnates.
In this in-depth discussion, Jerry shares:
- OnePrime’s journey from a retail-focused business to a global institutional liquidity provider
- What truly sets award-winning trading infrastructure apart
- Key trends shaping institutional trading, including technology and AI
- The importance of transparency, ethics, and reputation in long-term success
- OnePrime’s vision for growth over the next 12–24 months
Fresh from winning Finance Magnates’ Best Trading Infrastructure Broker, Jerry explains how experience, mentorship, and real-world problem solving form the “special sauce” behind OnePrime’s institutional offering.
🏆 Award Highlight: Best Trading Infrastructure Broker
👉 Subscribe to Finance Magnates for more executive interviews, market insights, and exclusive coverage from the world’s leading financial events.
#FMLS25 #FinanceMagnates #OnePrime #InstitutionalTrading #Liquidity #TradingInfrastructure #ExecutiveInterview
Recorded live at FMLS:25 London, this exclusive executive interview features Jerry Khargi, Executive Director at OnePrime, in conversation with Andrea Badiola Mateos from Finance Magnates.
In this in-depth discussion, Jerry shares:
- OnePrime’s journey from a retail-focused business to a global institutional liquidity provider
- What truly sets award-winning trading infrastructure apart
- Key trends shaping institutional trading, including technology and AI
- The importance of transparency, ethics, and reputation in long-term success
- OnePrime’s vision for growth over the next 12–24 months
Fresh from winning Finance Magnates’ Best Trading Infrastructure Broker, Jerry explains how experience, mentorship, and real-world problem solving form the “special sauce” behind OnePrime’s institutional offering.
🏆 Award Highlight: Best Trading Infrastructure Broker
👉 Subscribe to Finance Magnates for more executive interviews, market insights, and exclusive coverage from the world’s leading financial events.
#FMLS25 #FinanceMagnates #OnePrime #InstitutionalTrading #Liquidity #TradingInfrastructure #ExecutiveInterview
Recorded live at FMLS:25 London, this exclusive executive interview features Jerry Khargi, Executive Director at OnePrime, in conversation with Andrea Badiola Mateos from Finance Magnates.
In this in-depth discussion, Jerry shares:
- OnePrime’s journey from a retail-focused business to a global institutional liquidity provider
- What truly sets award-winning trading infrastructure apart
- Key trends shaping institutional trading, including technology and AI
- The importance of transparency, ethics, and reputation in long-term success
- OnePrime’s vision for growth over the next 12–24 months
Fresh from winning Finance Magnates’ Best Trading Infrastructure Broker, Jerry explains how experience, mentorship, and real-world problem solving form the “special sauce” behind OnePrime’s institutional offering.
🏆 Award Highlight: Best Trading Infrastructure Broker
👉 Subscribe to Finance Magnates for more executive interviews, market insights, and exclusive coverage from the world’s leading financial events.
#FMLS25 #FinanceMagnates #OnePrime #InstitutionalTrading #Liquidity #TradingInfrastructure #ExecutiveInterview
How does the Finance Magnates newsroom decide which updates are worth covering? #financenews
How does the Finance Magnates newsroom decide which updates are worth covering? #financenews
How does the Finance Magnates newsroom decide which updates are worth covering? #financenews
How does the Finance Magnates newsroom decide which updates are worth covering? #financenews
How does the Finance Magnates newsroom decide which updates are worth covering? #financenews
How does the Finance Magnates newsroom decide which updates are worth covering? #financenews
What makes an update worth covering in financial media?
According to Yam Yehoshua, Editor-in-Chief at Finance Magnates, editorial focus starts with relevance: stories that serve the industry, support brokers and technology providers, and help decision-makers navigate their businesses.
A reminder that strong financial journalism is built on value, not volume.
What makes an update worth covering in financial media?
According to Yam Yehoshua, Editor-in-Chief at Finance Magnates, editorial focus starts with relevance: stories that serve the industry, support brokers and technology providers, and help decision-makers navigate their businesses.
A reminder that strong financial journalism is built on value, not volume.
What makes an update worth covering in financial media?
According to Yam Yehoshua, Editor-in-Chief at Finance Magnates, editorial focus starts with relevance: stories that serve the industry, support brokers and technology providers, and help decision-makers navigate their businesses.
A reminder that strong financial journalism is built on value, not volume.
What makes an update worth covering in financial media?
According to Yam Yehoshua, Editor-in-Chief at Finance Magnates, editorial focus starts with relevance: stories that serve the industry, support brokers and technology providers, and help decision-makers navigate their businesses.
A reminder that strong financial journalism is built on value, not volume.
What makes an update worth covering in financial media?
According to Yam Yehoshua, Editor-in-Chief at Finance Magnates, editorial focus starts with relevance: stories that serve the industry, support brokers and technology providers, and help decision-makers navigate their businesses.
A reminder that strong financial journalism is built on value, not volume.
What makes an update worth covering in financial media?
According to Yam Yehoshua, Editor-in-Chief at Finance Magnates, editorial focus starts with relevance: stories that serve the industry, support brokers and technology providers, and help decision-makers navigate their businesses.
A reminder that strong financial journalism is built on value, not volume.